EVO
Price
$4.05
Change
+$0.04 (+1.00%)
Updated
Jun 6, 04:59 PM (EDT)
Capitalization
2.77B
68 days until earnings call
OGI
Price
$1.35
Change
+$0.04 (+3.05%)
Updated
Jun 6, 04:59 PM (EDT)
Capitalization
200.85M
Interact to see
Advertisement

EVO vs OGI

Header iconEVO vs OGI Comparison
Open Charts EVO vs OGIBanner chart's image
Evotec SE
Price$4.05
Change+$0.04 (+1.00%)
Volume$600
Capitalization2.77B
Organigram Global
Price$1.35
Change+$0.04 (+3.05%)
Volume$10.25K
Capitalization200.85M
EVO vs OGI Comparison Chart
Loading...
EVO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OGI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
EVO vs. OGI commentary
Jun 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EVO is a Hold and OGI is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 07, 2025
Stock price -- (EVO: $4.01 vs. OGI: $1.31)
Brand notoriety: EVO and OGI are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: EVO: 13% vs. OGI: 128%
Market capitalization -- EVO: $2.77B vs. OGI: $200.85M
EVO [@Pharmaceuticals: Other] is valued at $2.77B. OGI’s [@Pharmaceuticals: Other] market capitalization is $200.85M. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.78B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EVO’s FA Score shows that 1 FA rating(s) are green whileOGI’s FA Score has 0 green FA rating(s).

  • EVO’s FA Score: 1 green, 4 red.
  • OGI’s FA Score: 0 green, 5 red.
According to our system of comparison, OGI is a better buy in the long-term than EVO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EVO’s TA Score shows that 4 TA indicator(s) are bullish while OGI’s TA Score has 2 bullish TA indicator(s).

  • EVO’s TA Score: 4 bullish, 4 bearish.
  • OGI’s TA Score: 2 bullish, 6 bearish.
According to our system of comparison, EVO is a better buy in the short-term than OGI.

Price Growth

EVO (@Pharmaceuticals: Other) experienced а +6.08% price change this week, while OGI (@Pharmaceuticals: Other) price change was -5.07% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +79.53%. For the same industry, the average monthly price growth was +16.37%, and the average quarterly price growth was +68.04%.

Reported Earning Dates

EVO is expected to report earnings on Aug 13, 2025.

OGI is expected to report earnings on May 12, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (+79.53% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
EVO($2.77B) has a higher market cap than OGI($201M). EVO YTD gains are higher at: -3.606 vs. OGI (-18.634). EVO has higher annual earnings (EBITDA): -63.26M vs. OGI (-195.74M). EVO has more cash in the bank: 619M vs. OGI (42.3M). OGI has less debt than EVO: OGI (136K) vs EVO (589M). EVO has higher revenues than OGI: EVO (821M) vs OGI (161M).
EVOOGIEVO / OGI
Capitalization2.77B201M1,378%
EBITDA-63.26M-195.74M32%
Gain YTD-3.606-18.63419%
P/E Ratio476.19N/A-
Revenue821M161M510%
Total Cash619M42.3M1,463%
Total Debt589M136K433,088%
FUNDAMENTALS RATINGS
EVO vs OGI: Fundamental Ratings
EVO
OGI
OUTLOOK RATING
1..100
1113
VALUATION
overvalued / fair valued / undervalued
1..100
93
Overvalued
50
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9292
PRICE GROWTH RATING
1..100
5845
P/E GROWTH RATING
1..100
245
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

OGI's Valuation (50) in the null industry is somewhat better than the same rating for EVO (93). This means that OGI’s stock grew somewhat faster than EVO’s over the last 12 months.

OGI's Profit vs Risk Rating (100) in the null industry is in the same range as EVO (100). This means that OGI’s stock grew similarly to EVO’s over the last 12 months.

OGI's SMR Rating (92) in the null industry is in the same range as EVO (92). This means that OGI’s stock grew similarly to EVO’s over the last 12 months.

OGI's Price Growth Rating (45) in the null industry is in the same range as EVO (58). This means that OGI’s stock grew similarly to EVO’s over the last 12 months.

EVO's P/E Growth Rating (2) in the null industry is somewhat better than the same rating for OGI (45). This means that EVO’s stock grew somewhat faster than OGI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EVOOGI
RSI
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
83%
Momentum
ODDS (%)
Bullish Trend 2 days ago
67%
Bearish Trend 2 days ago
87%
MACD
ODDS (%)
Bearish Trend 2 days ago
74%
Bearish Trend 2 days ago
88%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
69%
Bearish Trend 2 days ago
85%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
70%
Bullish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 3 days ago
68%
Bullish Trend 3 days ago
83%
Declines
ODDS (%)
Bearish Trend 9 days ago
79%
Bearish Trend 5 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
76%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
65%
Bullish Trend 2 days ago
82%
View a ticker or compare two or three
Interact to see
Advertisement
EVO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OGI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FCSDX17.02N/A
N/A
Fidelity Advisor Strategic Div & Inc C
IVGSX22.81N/A
N/A
VY® Invesco Growth and Income S
CSGCX43.00N/A
N/A
Calvert Balanced C
FIJZX49.62N/A
N/A
Fidelity Advisor Consumer Discret Z
RCEAX9.80N/A
N/A
RBC China Equity A

OGI and

Correlation & Price change

A.I.dvisor indicates that over the last year, OGI has been closely correlated with SNDL. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if OGI jumps, then SNDL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OGI
1D Price
Change %
OGI100%
-2.24%
SNDL - OGI
67%
Closely correlated
N/A
ACB - OGI
61%
Loosely correlated
-2.93%
CGC - OGI
60%
Loosely correlated
+5.38%
TLRY - OGI
60%
Loosely correlated
-5.40%
CRON - OGI
59%
Loosely correlated
-1.04%
More